Jupiter Life Line Hospitals growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024
+18.9%+18.0%+19.8%
+15.7%+24.5%+18.3%
+6.7%+22.4%+20.3%
+2.9%+9.6%+142.2%
+0.4%+2.9%—
+25.1%+48.7%+30.0%
+13.9%+16.0%+221.2%
+5.7%+121.2%—
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

JLHL₹260.10

Jupiter Life Line Hospitals Ltd.

· Pharma & Health
₹ CrorePeersAPOLLOHOSPMAXHEALTHKIMSHCGMARKSANSMETROPOLISPARKHOSPSCORONAMcap ₹1,705 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+19.8+18.0+18.9—
EBITDA Growth—+18.3+24.5+15.7—
EBIT Growth—+20.3+22.4+6.7—
Net Income Growth—+142.2+9.6+2.9—
EPS Growth——+2.9+0.4—
Total Assets Growth—+30.0+48.7+25.1—
Total Equity Growth—+221.2+16.0+13.9—
Cash from Operations Growth——+121.2+5.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.